The rapid SARS-CoV-2 antibody qualitative test is accurate for assessing immunity following vaccination during pregnancy

The Biohit SARS-CoV-2 IgM/IgG antibody kit (Biohit Healthcare, Hefei, China) is a novel rapid immunochromatographic test for the qualitative detection of SARS-CoV-2 antibodies in human blood. It is intended to aid in identifying a prior infection within 20 minutes, can be obtained from capillary sampling, and was found to have a sensitivity and specificity of over 95% in the detection of antibodies two weeks after COVID-19 infection in a non-pregnant patient. Our aim was to assess the presence of antibodies at birth by the Biohit rapid test, in women vaccinated during pregnancy with the BNT162b2 mRNA COVID-19 Pfizer vaccine.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Poster Session II Source Type: research